Risk of bias assessments for the Cochrane review 'SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19'
Nina Kreuzberger(University of Cologne), Nicole Skoetz(Medical University of Vienna), Lise J Estcourt(NHS Blood and Transplant), Miriam Neidhardt(University of Cologne), Cynthia So‐Osman(Sanquin), Maria Popp(Universitätsklinikum Würzburg), Caroline Hirsch(University of Cologne), Ina Monsef(University of Cologne), Vanessa Piechotta(Robert Koch Institute), Susanne Salomon(University of Cologne), Erica M. Wood(Monash Health), E. Tomlinson(Unknown), Sarah J Valk(Leiden University Medical Center), Zoe McQuilten, David J. Roberts(NHS Blood and Transplant), Zahra Khosravi(University of Cologne), Khai Li Chai(Monash University)
Cited by 0
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.3k
SARS-CoV-2 evolution during treatment of chronic infection
|Nature|2021|1.1k
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
|JAMA|2020|884
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression
|The Lancet Infectious Diseases|2023|658
Patient Blood Management
|JAMA|2019|619